MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Trial Details

NCT ID
NCT05794880
Phase
NA
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Patient age \< 25 years. Both genders and all races eligible.
  • Disease eligibility
  • Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow MRD ≤ 0.1%)
  • Myelodysplasia

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →